临床实践指南:突发性听力损失(更新版)执行摘要
该指南由美国耳鼻咽喉头颈外科学会基金会更新,面向18岁及以上以突发性听力损失为主诉的成人,重点为特发性突发性感音神经性听力损失。方法为系统文献综述并按该基金会指南制定手册更新关键行动声明。强推荐包括:初诊时区分感音神经性与传导性听力损失、向患者说明自然病史与干预利弊及证据局限、对残留听力损失和/或耳鸣者告知听力康复等支持措施的可能获益;强推荐反对常规头颅CT、常规实验室检查及常规使用抗病毒药、溶栓药、血管扩张药或血管活性物质。推荐尽快(症状出现14天内)听力学确诊、评估耳蜗后病变、不完全恢复者2至6周内鼓室内激素治疗、治疗结束及6个月内随访听力学。激素初始治疗、高压氧联合激素治疗为选项。
要点
- 初诊突发性听力损失时,临床医生应区分感音神经性与传导性听力损失(KAS 1,强推荐)。
- 疑似突发性感音神经性听力损失初诊评估不应常规行头颅CT(KAS 3,强推荐反对);不应常规做实验室检查(KAS 5,强推荐反对)。
- 不应常规处方抗病毒药、溶栓药、血管扩张药或血管活性物质(KAS 11,强推荐反对)。
- 突发性听力损失应尽快、症状出现14天内获得或转诊行听力学检查以确诊(KAS 4,推荐)。
- 发病2至6周不完全恢复者应提供或转诊行鼓室内激素治疗(KAS 10,推荐);发病2周内可考虑激素初始治疗(KAS 8,选项)。
适用人群与场景
- 适用于诊断或管理以突发性听力损失为主诉的18岁及以上成人患者的全部临床医生。
- 重点人群为特发性突发性感音神经性听力损失患者;超过90%的突发性感音神经性听力损失为特发性。
- 需识别罕见的非特发性突发性感音神经性听力损失,将其与特发性者区分。
诊断标准与关键阈值
- 初诊突发性听力损失时,临床医生应区分感音神经性听力损失与传导性听力损失(KAS 1,强推荐)。
- 疑似突发性感音神经性听力损失应通过病史和体格检查评估双侧突发性听力损失、复发性突发性听力损失发作和/或局灶性神经系统体征(KAS 2,推荐)。
- 突发性听力损失患者应尽快、在症状出现14天内获得或转诊行听力学检查以确认突发性感音神经性听力损失诊断(KAS 4,推荐)。
处置流程与药物剂量
- 临床医生可对症状出现2周内的突发性感音神经性听力损失患者提供激素作为初始治疗(KAS 8,选项)。
- 临床医生可提供或转诊提供高压氧治疗联合激素治疗,用于突发性感音神经性听力损失发病2周内(KAS 9a,选项)。
- 临床医生可提供或转诊提供高压氧治疗联合激素治疗作为挽救治疗,用于突发性感音神经性听力损失发病1个月内(KAS 9b,选项)。
- 发病2至6周症状后不完全恢复的突发性感音神经性听力损失患者,应提供或转诊提供鼓室内激素治疗(KAS 10,推荐)。
- 突发性感音神经性听力损失患者应通过磁共振成像或听性脑干反应评估耳蜗后病变(KAS 6,推荐)。
- 突发性感音神经性听力损失患者应在治疗结束时及治疗完成后6个月内获得随访听力学评估(KAS 12,推荐)。
红旗征与不能漏的情况
- 病史和体格检查需评估双侧突发性听力损失、复发性突发性听力损失发作和/或局灶性神经系统体征,以识别需进一步评估的非特发性病因(KAS 2,推荐)。
研究设计与关键结果
- 指南更新组由耳鼻咽喉头颈外科、耳科、神经耳科、家庭医学、听力学、急诊医学、神经病学、放射学、高级实践护理和消费者倡导等学科代表组成,按美国耳鼻咽喉头颈外科学会基金会临床实践指南制定手册第三版进行系统文献综述并更新关键行动声明。
- 更新纳入10部临床实践指南、29篇新系统综述和36项新随机对照试验,证据概况纳入质量改进机会、证据信心和意见分歧。
- 强推荐3条:KAS 1区分感音神经性与传导性听力损失;KAS 7向患者说明自然病史、医疗干预利弊及现有疗效证据局限;KAS 13对残留听力损失和/或耳鸣者告知听力康复及其他支持措施的可能获益。
- 强推荐反对3条:KAS 3初诊疑似突发性感音神经性听力损失不常规行头颅CT;KAS 5不常规行实验室检查;KAS 11不常规处方抗病毒药、溶栓药、血管扩张药或血管活性物质。
- 推荐5条:KAS 2病史和体格检查评估双侧、复发和/或局灶神经系统体征;KAS 4症状出现14天内尽快听力学确诊;KAS 6磁共振成像或听性脑干反应评估耳蜗后病变;KAS 10发病2至6周不完全恢复者鼓室内激素治疗;KAS 12治疗结束及6个月内随访听力学。
- 选项3条:KAS 8发病2周内可提供激素初始治疗;KAS 9a发病2周内可提供高压氧联合激素治疗;KAS 9b发病1个月内可提供高压氧联合激素治疗作为挽救治疗。
- 与旧版相比,强调症状出现至评估和启动治疗(如提供治疗)的时效性,并将突发性感音神经性听力损失一词用于特指特发性突发性感音神经性听力损失。
证据类型、等级与局限
- 证据类型:临床实践指南(更新版),基于系统文献综述并按美国耳鼻咽喉头颈外科学会基金会临床实践指南制定手册第三版制定。
- 推荐等级:强推荐(KAS 1、KAS 7、KAS 13)、强推荐反对(KAS 3、KAS 5、KAS 11)、推荐(KAS 2、KAS 4、KAS 6、KAS 10、KAS 12)、选项(KAS 8、KAS 9a、KAS 9b)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊初诊突发性听力损失时应先区分感音神经性与传导性听力损失,再按疑似突发性感音神经性听力损失路径处理(KAS 1,强推荐)。
- 不应在初诊疑似突发性感音神经性听力损失时常规开具头颅CT(KAS 3,强推荐反对);不应常规开具实验室检查(KAS 5,强推荐反对)。
- 不应常规处方抗病毒药、溶栓药、血管扩张药或血管活性物质(KAS 11,强推荐反对)。
- 应尽快、症状出现14天内安排或转诊听力学检查以确诊(KAS 4,推荐),并在治疗结束及6个月内随访听力学(KAS 12,推荐)。
- 发病2周内可考虑激素初始治疗(KAS 8,选项);发病2周内可考虑高压氧联合激素治疗(KAS 9a,选项);发病1个月内可考虑高压氧联合激素治疗作为挽救治疗(KAS 9b,选项)。
- 发病2至6周不完全恢复者应提供或转诊鼓室内激素治疗(KAS 10,推荐)。
- 应向患者说明自然病史、干预利弊及证据局限(KAS 7,强推荐),并对残留听力损失和/或耳鸣者告知听力康复等支持措施的可能获益(KAS 13,强推荐)。
指南或共识出处
- Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary,美国耳鼻咽喉头颈外科学会基金会(American Academy of Otolaryngology-Head and Neck Surgery Foundation),Otolaryngol Head Neck Surg。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Sudden hearing loss is a frightening symptom that often prompts an urgent or emergent visit to a health care provider. It is frequently, but not universally, accompanied by tinnitus and/or vertigo. Sudden sensorineural hearing loss affects 5 to 27 per 100,000 people annually, with about 66,000 new cases per year in the United States. This guideline update provides evidence-based recommendations for the diagnosis, management, and follow-up of patients who present with sudden hearing loss. It focuses on sudden sensorineural hearing loss in adult patients aged 18 and over and primarily on those with idiopathic sudden sensorineural hearing loss. Prompt recognition and management of sudden sensorineural hearing loss may improve hearing recovery and patient quality of life. The guideline update is intended for all clinicians who diagnose or manage adult patients who present with sudden hearing loss.
PURPOSE: The purpose of this guideline update is to provide clinicians with evidence-based recommendations in evaluating patients with sudden hearing loss and sudden sensorineural hearing loss, with particular emphasis on managing idiopathic sudden sensorineural hearing loss. The guideline update group recognized that patients enter the health care system with sudden hearing loss as a nonspecific primary complaint. Therefore, the initial recommendations of this guideline update address distinguishing sensorineural hearing loss from conductive hearing loss at the time of presentation with hearing loss. They also clarify the need to identify rare, nonidiopathic sudden sensorineural hearing loss to help separate those patients from those with idiopathic sudden sensorineural hearing loss, who are the target population for the therapeutic interventions that make up the bulk of the guideline update. By focusing on opportunities for quality improvement, this guideline should improve diagnostic accuracy, facilitate prompt intervention, decrease variations in management, reduce unnecessary tests and imaging procedures, and improve hearing and rehabilitative outcomes for affected patients.
METHODS: Consistent with the American Academy of Otolaryngology-Head and Neck Surgery Foundation's Clinical Practice Guideline Development Manual, Third Edition, the guideline update group was convened with representation from the disciplines of otolaryngology-head and neck surgery, otology, neurotology, family medicine, audiology, emergency medicine, neurology, radiology, advanced practice nursing, and consumer advocacy. A systematic review of the literature was performed, and the prior clinical practice guideline on sudden hearing loss was reviewed in detail. Key action statements (KASs) were updated with new literature, and evidence profiles were brought up to the current standard. Research needs identified in the original clinical practice guideline and data addressing them were reviewed. Current research needs were identified and delineated.
RESULTS: The guideline update group made strong recommendations for the following: clinicians should distinguish sensorineural hearing loss from conductive hearing loss when a patient first presents with sudden hearing loss (KAS 1); clinicians should educate patients with sudden sensorineural hearing loss about the natural history of the condition, the benefits and risks of medical interventions, and the limitations of existing evidence regarding efficacy (KAS 7); and clinicians should counsel patients with sudden sensorineural hearing loss who have residual hearing loss and/or tinnitus about the possible benefits of audiological rehabilitation and other supportive measures (KAS 13). These strong recommendations were modified from the initial clinical practice guideline for clarity and timing of intervention. The guideline update group made strong recommendation against the following: clinicians should not order routine computed tomography of the head in the initial evaluation of a patient with presumptive sudden sensorineural hearing loss (KAS 3); clinicians should not obtain routine laboratory tests in patients with sudden sensorineural hearing loss (KAS 5); and clinicians should not routinely prescribe antivirals, thrombolytics, vasodilators, or vasoactive substances to patients with sudden sensorineural hearing loss (KAS 11). The guideline update group made recommendations for the following: clinicians should assess patients with presumptive sudden sensorineural hearing loss through history and physical examination for bilateral sudden hearing loss, recurrent episodes of sudden hearing loss, and/or focal neurologic findings (KAS 2); in patients with sudden hearing loss, clinicians should obtain, or refer to a clinician who can obtain, audiometry as soon as possible (within 14 days of symptom onset) to confirm the diagnosis of sudden sensorineural hearing loss (KAS 4); clinicians should evaluate patients with sudden sensorineural hearing loss for retrocochlear pathology by obtaining a magnetic resonance imaging or auditory brainstem response (KAS 6); clinicians should offer, or refer to a clinician who can offer, intratympanic steroid therapy when patients have incomplete recovery from sudden sensorineural hearing loss 2 to 6 weeks after onset of symptoms (KAS 10); and clinicians should obtain follow-up audiometric evaluation for patients with sudden sensorineural hearing loss at the conclusion of treatment and within 6 months of completion of treatment (KAS 12). These recommendations were clarified in terms of timing of intervention and audiometry, as well as method of retrocochlear workup. The guideline update group offered the following KASs as options: clinicians may offer corticosteroids as initial therapy to patients with sudden sensorineural hearing loss within 2 weeks of symptom onset (KAS 8); clinicians may offer, or refer to a clinician who can offer, hyperbaric oxygen therapy combined with steroid therapy within 2 weeks of onset of sudden sensorineural hearing loss (KAS 9a); and clinicians may offer, or refer to a clinician who can offer, hyperbaric oxygen therapy combined with steroid therapy as salvage therapy within 1 month of onset of sudden sensorineural hearing loss (KAS 9b).
DIFFERENCES FROM PRIOR GUIDELINE: Incorporation of new evidence profiles to include quality improvement opportunities, confidence in the evidence, and differences of opinion Included 10 clinical practice guidelines, 29 new systematic reviews, and 36 new randomized controlled trials Highlights the urgency of evaluation and initiation of treatment, if treatment is offered, by emphasizing the time from symptom occurrence Clarification of terminology by changing potentially unclear statements; use of the term sudden sensorineural hearing loss to mean idiopathic sudden sensorineural hearing loss to emphasize that over 90% of sudden sensorineural hearing loss is idiopathic sudden sensorineural hearing loss and to avoid confusion in nomenclature for the reader Changes to the key action statements (KASs) from the original guideline: KAS 1: When a patient first presents with sudden hearing loss, conductive hearing loss should be distinguished from sensorineural. KAS 2: The utility of history and physical examination when assessing for modifying factors is emphasized. KAS 3: The word routine is added to clarify that this statement addresses a nontargeted head computed tomography scan that is often ordered in the emergency room setting for patients presenting with sudden hearing loss. It does not refer to targeted scans such as a temporal bone computed tomography scan to assess for temporal bone pathology. KAS 4: The importance of audiometric confirmation of hearing status as soon as possible and within 14 days of symptom onset is emphasized. KAS 5: New studies were added to confirm the lack of benefit of nontargeted laboratory testing in sudden sensorineural hearing loss. KAS 6: Audiometric follow-up is excluded as a reasonable workup for retrocochlear pathology. Magnetic resonance imaging, computed tomography scan if magnetic resonance imaging cannot be done, or, secondarily, auditory brainstem response evaluation are the modalities recommended. A time frame for such testing is not specified, nor is it specified which clinician should be ordering this workup; however, it is implied that it would be the general or subspecialty otolaryngologist. KAS 7: The importance of shared decision making is highlighted, and salient points are emphasized. KAS 8: The option for corticosteroid intervention within 2 weeks of symptom onset is emphasized. KAS 9: Changed to KAS 9a and 9b; hyperbaric oxygen therapy remains an option but only when combined with steroid therapy for either initial treatment (9a) or for salvage therapy (9b). The timing is within 2 weeks of onset for initial therapy and within 1 month of onset of sudden sensorineural hearing loss for salvage therapy. KAS 10: Intratympanic steroid therapy for salvage is recommended within 2 to 6 weeks following onset of sudden sensorineural hearing loss. The time to treatment is defined and emphasized. KAS 11: Antioxidants were removed from the list of interventions that the clinical practice guideline recommends against using. KAS 12: Follow-up audiometry at conclusion of treatment and also within 6 months posttreatment is added. KAS 13: This statement on audiologic rehabilitation includes patients who have residual hearing loss and/or tinnitus who may benefit from treatment. Addition of an algorithm outlining KASs Enhanced emphasis on patient education and shared decision making with tools provided to assist in the same.
参考来源
- Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary. Otolaryngol Head Neck Surg. 2019. PMID: 31369349. doi:10.1177/0194599819859883
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。